Cross-regulation between FOXA1 and ErbB2 signaling in estrogen receptor-negative breast cancer

Neoplasia

Volumn 14, Issue 4, 2012, Pages 283-296

  Naderi, Ali ^a   Meyer, Michelle ^a   Dowhan, Dennis H ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; P21 ACTIVATED KINASE 1; PROTEIN C FOS; TRANSCRIPTION FACTOR AP 2; TRANSCRIPTION FACTOR RELB;

APOCRINE CARCINOMA; ARTICLE; BREAST CANCER; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

EID: 84860607999     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.12294     Document Type: Article

References (58)

1. Putti TC, El-Rehim DM, Rakha EA, Paish CE, Lee AH, Pinder SE, and Ellis IO (2005). Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol 18, 26-35.
2. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, Macgrogan G, Bergh J, Cameron D, Goldstein D, et al. (2005). Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 24, 4660-4671.
3. Teschendorff AE, Naderi A, Barbosa-Morais NL, and Caldas C (2006). PACK: profile analysis using clustering and kurtosis to find molecular classifiers in cancer. Bioinformatics 15, 2269-2275.
4. Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C, and Gerald WL (2006). An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 25, 3994-4008.
5. Park S, Koo J, Park HS, Kim JH, Choi SY, Lee JH, Park BW, and Lee KS (2010). Expression of androgen receptors in primary breast cancer. Ann Oncol 21, 488-492.
6. Collins LC, Cole KS, Marotti JD, Hu R, Schnitt SJ, and Tamimi RM (2011). Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study. Mod Pathol 24, 924-931.
7. Niemeier LA, Dabbas DJ, Beriwal S, Striebel JM, and Bhargava R (2009). Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol 23, 205-212.
8. Naderi A and Hughes-Davies L (2008). A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. Neoplasia 10, 542-548.
9. Chia KM, Liu J, Francis GD, and Naderi A (2011). A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer. Neoplasia 13, 154-166.
10. Ni M, Chen Y, Lim E, Wimberly H, Bailey ST, Imai Y, Rimm DL, Liu XS, and Brown M (2011). Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell 20, 119-131.
11. Naderi A, Chia KM, and Liu J (2011). Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer. Breast Cancer Res 13, R36.
12. Naderi A and Liu J (2010). Inhibition of androgen receptor and Cdc25A phosphatase as a combination targeted therapy in molecular apocrine breast cancer. Cancer Lett 298, 74-87.
13. Gucalp A and Traina TA (2010). Triple-negative breast cancer: role of the androgen receptor. Cancer J 16, 62-65.
14. Augello MA, Hickey TE, and Knudsen KE (2011). FOXA1: master of steroid receptor function in cancer. EMBO J 30, 3885-3894.
15. Sahu B, Laakso M, Ovaska K, Mirtti T, Lundin J, Rannikko A, Sankila A, Turunen JP, Lundin M, Konsti J, et al. (2011). Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO J 30, 3962-3976.
16. Robinson JL, Macarthur S, Ross-Innes CS, Tilley WD, Neal DE, Mills IG, and Carroll JS (2011). Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO J 30, 3019-3027.
17. Nakshatri H and Badve S (2009). FOXA1 in breast cancer. Exp Rev Mol Med 11, e8.
18. Bernardo GM and Keri RA (2012). FOXA1: a transcription factor with parallel functions in development and cancer. Biosci Rep 32, 113-130.
19. Wang D, Garcia-Bassets I, Benner C, Li W, Su X, Zhou Y, Qiu J, Liu W, Kaikkonen MU, Ohgi KA, et al. (2011). Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature 474, 390-394.
20. Laganiere J, Deblois G, Lefebvre C, Bataille AR, Robert F, and Giguere V (2005). From the cover: location analysis of estrogen receptor α target promoters reveals that FOXA1 defines a domain of the estrogen response. Proc Natl Acad Sci USA 102, 11651-11656.
21. Kouros-Mehr H, Slorach EM, Sternlicht MD, and Werb Z (2006). GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell 127, 1041-1055.
22. Sircoulomb F, Bekhouche I, Finetti P, Adelaide J, Ben Hamida A, Bonansea J, Raynaud S, Innocenti C, Charafe-Jauffret E, Tarpin C, et al. (2010). Genome profiling of ERBB2-amplified breast cancers. BMC Cancer 10, 539.
23. Naderi A, Liu J, and Francis GD (2012). A feedback loop between BEX2 and ErbB2 mediated by c-Jun signaling in breast cancer. Int J Cancer 130, 71-82.
24. Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, Wang X, Wu L, Li J, Hu M, Gong Y, et al. (2010). An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 17, 443-454.
25. Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali HR, Dunning MJ, Brown GD, Gojis O, Ellis IO, Green AR, et al. (2012). Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 481, 389-393.
26. Thorat MA, Marchio C, Morimiya A, Savage K, Nakshatri H, Reis-Filho JS, and Badve S (2008). Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis. J Clin Pathol 61, 327-332.
27. Tomozawa S, Tsuno NH, Sunami E, Hatano K, Kitayama J, Osada T, Saito S, Tsuruo T, Shibata Y, and Nagawa H (2000). Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. Br J Cancer 83, 324-328.
28. Camilleri-Broet S, Hardy-Bessard AC, Le Tourneau A, Paraiso D, Levrel O, Leduc B, Bain S, Orfeuvre H, Audouin J, and Pujade-Lauraine E (2004). HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group. Ann Oncol 15, 104-112.
29. Naderi A, Teschendorff AE, Beigel M, Cariati M, Ellis IO, Brenton JD, and Caldas C (2007). BEX2 is overexpressed in a subset of primary breast cancers and mediates nerve growth factor/nuclear factor-κB inhibition of apoptosis in breast cancer cell lines. Cancer Res 67, 6725-6736.
30. Naderi A, Liu J, and Bennett IC (2010). BEX2 regulates mitochondrial apoptosis and G1 cell cycle in breast cancer. Int J Cancer 126, 1596-1610.
31. Ma XL, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A, Muir B, Mohapatra G, Salunga R, Tuggle JT, et al. (2004). A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5, 607-616.
32. Naderi A, Liu J, and Hughes-Davies L (2010). BEX2 has a functional interplay with c-Jun/JNK and p65/RelA in breast cancer. Mol Cancer 19, 111.
33. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, et al. (2006). A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10, 515-527.
34. Mehta RJ, Jain RK, Leung S, Choo J, Nielsen T, Huntsman D, Nakshatri H, and Badve S (2012). FOXA1 is an independent prognostic marker for ERpositive breast cancer. Breast Cancer Res Treat 131, 881-890.
35. Vernimmen D, Gueders M, Pisvin S, Delvenne P, and Winkler R (2003). Different mechanisms are implicated in ERBB2 gene overexpression in breast and in other cancers. Br J Cancer 89, 899-906.
36. Vernimmen D, Begon D, Salvador C, Gofflot S, Grooteclaes M, and Winkler R (2003). Identification of HTF (HER2 transcription factor) as an AP-2 (activator protein-2) transcription factor and contribution of the HTF binding site to ERBB2 gene overexpression. Biochem J 370, 323-329.
37. Perissi V, Menini N, Cottone E, Capello D, Sacco M, Montaldo F, and De Bortoli M (2000). AP-2 transcription factors in the regulation of ERBB2 gene transcription by oestrogen. Oncogene 19, 280-288.
38. Allouche A, Nolens G, Tancredi A, Delacroix L, Mardaga J, Fridman V, Winkler R, Boniver J, Delvenne P, and Begon DY (2008). The combined immunodetection of AP-2α and YY1 transcription factors is associated with ERBB2 gene overexpression in primary breast tumors. Breast Cancer Res 10, R9.
39. Begon DY, Delacroix L, Vernimmen D, Jackers P, and Winkler R (2005). Yin Yang 1 cooperates with activator protein 2 to stimulate ERBB2 gene expression in mammary cancer cells. J Biol Chem 280, 24428-24434.
40. Bosher JM, Williams T, and Hurst HC (1995). The developmentally regulated transcription factor AP-2 is involved in c-erbB-2 overexpression in human mammary carcinoma. Proc Natl Acad Sci USA 92, 744-747.
41. Adiseshaiah P, Li J, Vaz M, Kalvakolanu DV, and Reddy SP (2008). ERK signaling regulates tumor promoter induced c-Jun recruitment at the Fra-1 promoter. Biochem Biophys Res Commun 371, 304-308.
42. Lonze BE and Ginty DD (2002). Function and regulation of CREB family transcription factors in the nervous system. Neuron 35, 605-623.
43. Xing J, Ginty D, and Greenberg ME (1996). Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase. Science 273, 959-963.
44. De Cesare D, Jacquot S, Hanauer A, and Sassone-Corsi P (1998). Rsk-2 activity is necessary for epidermal growth factor-induced phosphorylation of CREB protein and transcription of c-fos gene. Proc Natl Acad Sci USA 95, 12202-12207.
45. Yang SH, Yates PR, Whitmarsh AJ, Davis RJ, and Sharrocks AD (1998). The Elk-1 ETS-domain transcription factor contains a mitogen-activated protein kinase targeting motif. Mol Cell Biol 18, 710-720.
46. Wang Y and Prywes R (2000). Activation of the c-fos enhancer by the Erk MAP kinase pathway through two sequence elements: the c-fos AP-1 and p62TCF sites. Oncogene 19, 1379-1385.
47. Sekiya T and Zaret KS (2007). Repression by Groucho/TLE/Grg proteins: genomic site recruitment generates compacted chromatin in vitro and impairs activator binding in vivo. Mol Cell 28, 291-303.
48. Eeckhoute J, Lupien M, Meyer CA, Verzi MP, Shivdasani RA, Liu XS, and Brown M (2009). Cell-type selective chromatin remodeling defines the active subset of FOXA1-bound enhancers. Genome Res 19, 372-380.
49. Yamaguchi N, Ito E, Azuma S, Honma R, Yanagisawa Y, Nishikawa A, Kawamura M, Imai J, Tatsuta K, Inoue J, et al. (2008). FoxA1 as a lineagespecific oncogene in luminal type breast cancer. Biochem Biophys Res Commun 365, 711-717.
50. Du K and Montminy M (1998). CREB is a regulatory target for the protein kinase Akt/PKB. J Biol Chem 273, 32377-32379.
51. Monje P, Hernandez-Losa J, Lyons RJ, Castellone MD, and Gutkind JS (2005). Regulation of the transcriptional activity of c-Fos by ERK. A novel role for the prolyl isomerase PIN1. J Biol Chem 280, 35081-35084.
52. Xu TR, Vyshemirsky V, Gormand A, von Kriegsheim A, Girolami M, Baillie GS, Ketley D, Dunlop AJ, Milligan G, Houslay MD, et al. (2010). Inferring signaling pathway topologies from multiple perturbation measurements of specific biochemical species. Sci Signal 3, ra20.
53. Nagata Y, Honda Y, and Matsuda R (2010). FGF2 induces ERK phosphorylation through Grb2 and PKC during quiescent myogenic cell activation. Cell Struct Funct 35, 63-71.
54. Lu L, Wang LL, Li T, and Wang J (2010). NF-κB subtypes regulate CCCTC binding factor affecting corneal epithelial cell fate. J Biol Chem 285, 9373-9382.
55. Van Laere SJ, Van der Auwera I, Van den Eynden GG, van Dam P, Van Marck EA, Vermeulen PB, and Dirix LY (2007). NF-κB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation. Br J Cancer 97, 659-669.
56. Biswas DK, Cruz AP, Gansberger E, and Pardee AB (2000). Epidermal growth factor-induced nuclear factor κB activation: a major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci USA 97, 8542-8547.
57. Oeckinghaus A, Hayden MS, and Ghosh S (2011). Crosstalk in NF-κB signaling pathways. Nat Immunol 12, 695-708.
58. Puto LA, Pestonjamasp K, King CC, and Bokoch GM (2003). p21-activated kinase 1 (PAK1) interacts with the Grb2 adapter protein to couple to growth factor signaling. J Biol Chem 278, 9388-9393.